156 related articles for article (PubMed ID: 19857794)
1. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
2. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
3. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
4. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
5. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
Gocke E; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
[TBL] [Abstract][Full Text] [Related]
6. The Viracept-EMS case: impact and outlook.
Walker VE; Casciano DA; Tweats DJ
Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
[TBL] [Abstract][Full Text] [Related]
7. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
[TBL] [Abstract][Full Text] [Related]
8. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
Gocke E; Bürgin H; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
[TBL] [Abstract][Full Text] [Related]
10. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
Gocke E; Wall M
Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
[TBL] [Abstract][Full Text] [Related]
11. General 4-week toxicity study with EMS in the rat.
Pfister T; Eichinger-Chapelon A
Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
[TBL] [Abstract][Full Text] [Related]
12. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
Müller L; Gocke E
Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
[TBL] [Abstract][Full Text] [Related]
13. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
[TBL] [Abstract][Full Text] [Related]
14. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
15. In-utero exposure to nelfinavir-ethyl methyl sulfone.
Hleyhel M; Goujon S; Sibiude J; Blanche S; Warszawski J;
AIDS; 2016 Nov; 30(17):2729-2730. PubMed ID: 27662548
[TBL] [Abstract][Full Text] [Related]
16. Changes are recommended in use of nelfinavir.
Wilcox RD
HIV Clin; 2008; 20(1):1, 4. PubMed ID: 18578034
[No Abstract] [Full Text] [Related]
17. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
18. Viracept contaminated in Europe.
AIDS Patient Care STDS; 2007 Jul; 21(7):521. PubMed ID: 17651033
[No Abstract] [Full Text] [Related]
19. Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.
Pozniak A; Müller L; Salgo M; Jones JK; Larson P; Tweats D
AIDS Res Ther; 2009 Aug; 6():18. PubMed ID: 19660105
[TBL] [Abstract][Full Text] [Related]
20. FDA notifications. FDA provides more info in response to Viracept recall.
AIDS Alert; 2007 Nov; 22(11):129-31. PubMed ID: 18411458
[No Abstract] [Full Text] [Related]
[Next] [New Search]
